TP53 modiated alonal homotopoissis confors increased risk for
incident peripheral artery disease

- 4 Seyedeh M. Zekavat BS^{1-4*}, Vanesa Viana-Huete PhD^{5*}, María A. Zuriaga PhD⁵, Md Mesbah
- Uddin PhD^{3,4}, Mark Trinder BS^{3,4,6}, Kaavya Paruchuri MD^{3,4,7}, Nuria Matesanz PhD⁵, Virginia 5
- Zorita BS MSc⁵, Alba Ferrer-Pérez BS MSc⁵, Marta Amorós-Pérez BS MSc⁵, Scott M. 6
- Damrauer MD⁸, Christie M. Ballantyne MD⁹, Abhishek Niroula PhD^{3,10}, Christopher J. Gibson 7
- MD¹⁰, James Pirruccello MD³, Gabriel Griffin MD¹¹, Benjamin L. Ebert MD PhD¹², Peter Libby 8
- MD PhD⁷, Valentín Fuster MD PhD^{5,13}, Hongyu Zhao PhD¹⁴, Pradeep Natarajan MD 9

10 MMSc^{3,4,7§}, Alexander G. Bick MD PhD^{3,15§}, José J Fuster PhD^{5,16§}, Derek Klarin MD^{3,17,18§}

11

1 2 3

- 12 Yale School of Medicine, New Haven, CT; 1.
- 13 Computational Biology & Bioinformatics Program, Yale University, New Haven, CT, USA; 2.
- 14 Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA; 3.
- 15 Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA; 4.
- 16 Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; 5.
- 17 Center for Heart Lung Innovation. University of British Columbia. Vancouver: 6.
- 18 Department of Medicine, Harvard Medical School, Boston, MA, USA; 7.
- 19 8. Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;
- 20 9. Center for Cardiometabolic Disease Prevention. Baylor College of Medicine, Houston, TX, USA:
- 21 10. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;
- 22 23 24 11. Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA;
- 12. Department of Hematology, Brigham and Women's Hospital, Boston, MA, USA;
- 13. Icahn School of Medicine at Mount Sinai, New York, NY, USA;
- 25 14. Department of Biostatistics, Yale School of Public Health, New Haven, CT;
- 26 15. Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, TN, USA;
- 27 16. CIBER en Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain;
- 28 17. Malcolm Randall VA Medical Center, Gainesville, FL;
- 29 18. Division of Vascular Surgery, University of Florida College of Medicine, FL, USA
- 30 31

* Co-first authors

- 32 § Equally supervised this work
- 33
- 34 Corresponding Authors:
- 35 Jose J. Fuster, PhD
- 36 jjfuster@cnic.es
- 37 Melchor Fernández Almagro, 3
- 38 28029 - Madrid (Spain)
- 39 Tel: (+34) 914531200, ext 4304
- 40 Fax: (+34) 914531265
- Twitter: @josejfuster 41
- 42 ORCID: 0000-0002-5970-629X
- 43 Derek Klarin, MD
- 44 derek.klarin@surgery.ufl.edu
- 1600 SW Archer Road, NG-45, PO Box 100128, Gainesville, FL 32610 45
- 46 Tel: 352-273-5485
- 47 Fax: 352-273-5515
- 48 ORCID: 0000-0002-4636-5780
- 49

50 Main Text Total word count: 3,517

51 **Funding:** P.N. is supported by a Hassenfeld Scholar Award from the Massachusetts General 52 Hospital, grants from the National Heart, Lung, and Blood Institute (R01HL1427,

- 53 R01HL148565, and R01HL148050), and from Fondation Leducg (TNE-18CVD04). S.M.Z is
- 54 supported by the NIH National Heart, Lung, and Blood Institute (1F30HL149180-01) and the
- 55 NIH Medical Scientist Training Program Training Grant (T32GM136651). A.G.B. is supported
- 56 by a Burroughs Wellcome Fund Career Award for Medical Scientists, a NIH Director Early
- 57 Independence Award (DP5-OD029586) and a NHLBI BioData Catalyst Fellowship (OT3
- 58 HL147154-01). J.P.P is supported by a John S LaDue Memorial Fellowship. K.P. is supported
- by NIH grant 5-T32HL007208-43. J.J.F. is supported by grants RYC-2016-20026 and RTI2018-
- 60 093554-A-I00) from the Spanish "Ministerio de Ciencia e Innovación", a 2019 Leonardo Grant
- 61 for Researchers and Cultural Creators from the BBVA Foundation, the European Research Area
- 62 Network on Cardiovascular Diseases CHEMICAL (grant AC19/00133 from the "Spanish
- 63 Instituto de Salud Carlos III") and the Leducq Foundation (TNE-18CVD04). The project leading
- 64 to these results received funding from "la Caixa" Foundation (ID 100010434), under agreement
- 65 HR17-00267. The Centro Nacional de Investigaciones Cardiovasculares (CNIC) is supported by
- 66 the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación and the Pro
- 67 CNIC Foundation. P.L. receives funding support from the National Heart, Lung, and Blood
- 68 Institute (1R01HL134892), the American Heart Association (18CSA34080399), the RRM
- 69 Charitable Fund, and the Simard Fund.
- 70

71 **Disclosures:** P.N. reported grants from Amgen during the conduct of the study and grants from

- 72 Boston Scientific; grants and personal fees from Apple; personal fees from Novartis and
- 73 Blackstone Life Sciences; and spousal employment at Vertex all outside the submitted work.
- 74 P.L. is an unpaid consultant to, or involved in clinical trials for Amgen, AstraZeneca, Baim
- 75 Institute, Beren Therapeutics, Esperion, Therapeutics, Genentech, Kancera, Kowa
- 76 Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Merck, Novartis, Pfizer, Sanofi-
- 77 Regeneron. Dr. Libby is a member of scientific advisory board for Amgen, Corvidia
- 78 Therapeutics, DalCor Pharmaceuticals, Kowa Pharmaceuticals, Olatec Therapeutics,
- 79 Medimmune, Novartis, and XBiotech, Inc. P.L.'s laboratory has received research funding in the
- 80 last 2 years from Novartis, he is on the Board of Directors of XBiotech, Inc, and has a financial
- 81 interest in Xbiotech, a company developing therapeutic human antibodies. These interests were
- 82 reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in
- 83 accordance with their conflict of interest policies. The other authors do not report any
- 84 disclosures.
- 85
- 86 **Acknowledgments:** Thanks to the participants and staff of the UK Biobank and Mass General
- Brigham Biobank. UK Biobank analyses were conducted using Application 7089. Thanks to Dr.
 Zeyan Liew and teaching fellow Jiajun Lu, the instructors of the causal inference course at Yale.
- 89
- <u>Abbreviations:</u> CHIP, clonal hematopoiesis of indeterminate potential; PAD, peripheral artery
 disease

92 Abstract

93 Background: Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate 94 potential (CHIP), particularly in DNMT3A, TET2, and JAK2, are associated with an increased 95 risk of hematologic malignancy, coronary artery disease, and all-cause mortality. However, 96 whether CHIP is associated with increased risk of peripheral artery disease (PAD) remains 97 unknown. In addition, chemotherapy frequently causes mutations in DNA Damage Repair 98 (DDR) genes TP53 and PPM1D, and whether CHIP caused by somatic mutations in DDR genes 99 results in increased risk of atherosclerosis is unclear. We sought to test whether CHIP, and CHIP 100 caused by DDR genes, associates with incident peripheral artery disease (PAD) and 101 atherosclerosis. 102 Methods: We identified CHIP among 50,122 exome sequences in individuals from UK and 103 Mass General Brigham Biobanks and tested CHIP status (N=2,851) with incident PAD and 104 atherosclerosis across multiple arterial beds. To mimic the human scenario of clonal 105 hematopoiesis and test whether the expansion of p53-deficient hematopoietic cells contributes to 106 atherosclerosis, a competitive bone marrow transplantation (BMT) strategy was used to generate 107 atherosclerosis-prone Ldlr-/- chimeric mice carrying 20% Trp53-/- hematopoietic cells (20% 108 KO-BMT mice). We then evaluated aortic plaque burden and plaque macrophage accumulation 109 12 weeks after grafting. 110 **Results:** CHIP associated with incident PAD (HR 1.7; P=2.2x10⁻⁵) and atherosclerosis in 111 multiple beds (HR 1.3; $P=9.7 \times 10^{-5}$), with increased risk among individuals with DDR CHIP (HR 112 2.0; P=0.0084). Among atherosclerosis-prone Ldlr null mice, the p53 -/- 20% KO-BMT mice 113 demonstrated increased aortic plaque size (p=0.013) and accumulation of p53-/- plaque 114 macrophages (P<0.001), driven by an abundance of p53-deficient plaque macrophages. The

115	expansion of p53-deficient	cells did not affect the	expression of the	pro-inflammatory	cytokines
-----	----------------------------	--------------------------	-------------------	------------------	-----------

- 116 IL-6 and IL-1 β in the atherosclerotic aortic wall.
- **Conclusions:** Our findings highlight the role of CHIP as a broad driver of atherosclerosis across
- 118 the entire arterial system, with evidence of increased plaque among p53 -/- 20% KO-BMT mice
- 119 via expansion of plaque macrophages. These observations provide new insight into the link
- 120 between CHIP and cardiovascular disease, and lend human genetic support to the concept that
- 121 post-cytotoxic chemotherapy patients may benefit from surveillance for atherosclerotic
- 122 conditions in addition to therapy-related myeloid neoplasms.

124 Abstract Word Count: 346

- 125 Key Words: somatic, atherosclerosis, clonal hematopoiesis, sequencing

139 Introduction

140 Peripheral artery disease (PAD) is a leading cause of cardiovascular morbidity and mortality 141 worldwide, and age is among its strongest risk factors. PAD associates with an extremely high 142 cardiovascular mortality and unmitigated can progress to limb loss¹. The age-related acquisition 143 and expansion of leukemogenic mutations in hematopoietic stem cells has recently been 144 associated with an increased risk of hematologic malignancy, coronary artery disease, and 145 overall mortality^{2, 3}. This phenomenon, termed clonal hematopoiesis of indeterminate potential 146 (CHIP), is relatively common in asymptomatic older adults, affecting at least 10% of individuals 147 older than 70 years of age⁴. CHIP mutations most frequently occur in epigenetic regulators 148 DNMT3A and TET2, in DNA damage repair (DDR) genes PPM1D and TP53, or cell cycle and transcriptional regulator genes JAK2 and ASXL15. CHIP associates with coronary artery disease 149 150 in multiple studies^{2, 6}. Whether CHIP links with increased risk of atherosclerosis in the peripheral 151 arterial bed (PAD) is unknown. 152 Here, we leveraged 50,122 whole exome sequences from two genetic biobanks (UK 153 Biobank [UKB], Mass General Brigham Biobank [MGBB]) and tested whether CHIP was associated with increased risk of PAD and atherosclerosis across multiple arterial beds, and 154 155 additionally whether these associations varied by putative CHIP driver gene. Based on these 156 results, we then performed functional analyses in Ldlr-null mice transplanted with 20% Trp53-/-157 bone marrow cells, a murine model of atherosclerosis and clonal hematopoiesis driven by TP53 158 mutations. 159

160 Methods

161 Cohorts and exclusion criteria

162	The UKB is a population-based cohort of approximately 500,000 participants recruited from
163	2006-2010 with existing genomic and longitudinal phenotypic data and median 10-year follow-
164	up ⁷ . Baseline assessments were conducted at 22 assessment centres across the UK with sample
165	collections including blood-derived DNA. Of ~49,960 individuals with WES data available, we
166	analyzed 37,657 participants consenting to genetic analyses after our exclusion criteria. Use of
167	the data was approved by the Massachusetts General Hospital Institutional Review Board
168	(protocol 2013P001840) and facilitated through UK Biobank Application 7089.
169	The MGBB contains genotypic and clinical data from >105,000 patients who consented
170	to broad-based research across 7 regional hospitals and median 3-year follow-up ⁸ . Baseline
171	phenotypes were ascertained from the electronic medical record and surveys. We analyzed
172	12,465 individuals consenting to genetic analysis after our exclusion criteria. Use of the data was
173	approved by the Massachusetts General Hospital Institutional Review Board (protocol
174	2020P000904).
175	Across both cohorts, we excluded individuals with prevalent hematologic cancer,
176	individuals without genotypic-phenotypic sex concordance, and one of each pair of 1st or 2nd
177	degree relatives at random. For the UKB, samples were further restricted to individuals with
178	Townsend deprivation index, a marker of socioeconomic status, available for analysis. Follow-up
179	time was defined as time from enrollment to disease diagnosis for cases, or to censorship or
180	death for controls.

181

182 *Whole exome sequencing and CHIP calling*

183 UKB WES were generated from whole blood-derived DNA at the Regeneron Sequencing

184 Center⁹. MGBB WES were generated using whole blood-derived DNA using Illumina

sequencing (mean coverage 55x). Somatic CHIP variants were detected with GATK MuTect2

186	software with parameters as previously described ^{6, 10} . Common germline variants and sequencing
187	artifacts were excluded as before. Samples were annotated with the presence of any CHIP if
188	MuTect2 identified one or more of a pre-specified list of pathogenic somatic variants, as
189	previously described ^{11, 12} . Additionally, samples were annotated with the presence of Large
190	CHIP (variant allele frequency >10%), as larger CHIP clones have previously been more
191	strongly associated with adverse clinical outcomes ⁶ .
192	
193	Phenotype definitions
194	Across both UKB and MGBB, PAD was defined by grouping together ICD-10 and ICD-9 billing
195	codes for aortic atherosclerosis (I70), peripheral vascular disease (I73.8, I73.9), and operative
196	procedures including amputation of leg (X09.3-5), bypass of artery of leg (L21.6, L51.3, L51.6,
197	L51.8, L59.1-8), endarterectomy or angioplasty of leg artery (L52.1-2, L54.1,4,8, L60.1-2,
198	L63.1,5), and other transluminal operations on leg arteries or peripheral stent placement
199	(L63.9,L66.7), as previously described ¹³ . Additionally, in the UKB self-reported peripheral
200	vascular disease, leg claudication/intermittent claudication, arterial embolism, femoral-popliteal
201	leg artery bypass, leg artery angioplasty +/- stent, or amputation of leg were also incorporated
202	(Data fields 20002, 20004) as performed previously ¹³ . Coronary artery disease and cerebral
203	atherosclerosis phenotype definitions for each cohort are detailed in Tables I and II in the
204	supplement. Other atherosclerotic conditions were defined using the Phecode Map 1.2 ¹⁴ ICD-9
205	(https://phewascatalog.org/phecodes) and ICD-10 (https://phewascatalog.org/phecodes_icd10)
206	phenotype groupings for "abdominal aortic aneurysm", "aortic aneurysm", "other aneurysm",
207	"chronic vascular insufficiency of intestine", "acute vascular insufficiency of intestine",

208 "atherosclerosis of renal artery". The composite atherosclerosis phenotype was created by 209 combining all analyzed atherosclerosis phenotypes (including PAD, coronary artery disease, 210 cerebral atherosclerosis, abdominal aortic aneurysm, aortic aneurysm, other aneurysm, chronic 211 vascular insufficiency of intestine, acute vascular insufficiency of intestine, and atherosclerosis 212 of renal artery) into one phenotype, whereby the first instance across all of these phenotypes was 213 used to determine time of first diagnosed atherosclerotic disease for survival analysis. Other 214 phenotypic covariates (never/prior/current smoking status, hypertension, hyperlipidemia, 215 principal components of ancestry, etc.) were used as previously defined¹⁵. 216 217 Association Analysis 218 In the UKB and MGBB a traditional cox-proportional hazards model was utilized using the 219 Survival package in R-3.5 adjusting for age, age², sex, smoking status, normalized Townsend 220 deprivation index as a marker of socioeconomic status (only available in UKB), and the first ten 221 principal components of genetic ancestry. Demographic and clinical characteristics found to 222 differ between individuals with and without CHIP were tested using chi-squared (categorical) 223 and Wilcoxon-rank sum (continuous) tests with a two-tailed P< 0.05 determining significance. 224 Sensitivity analysis including other covariates (normalized BMI, prevalent hypertension, 225 prevalent Type 2 diabetes, and prevalent hyperlipidemia) was not found to significantly change 226 associations with PAD in the UKB (Figure I in the supplement). Additional sensitivity 227 analyses were utilized in the UKB including propensity score adjustment, as well as a marginal 228 structural cox proportional hazards model estimated through stabilized inverse-probabilitytreatment-weight (IPTW)¹⁶ to estimate the total causal effect of CHIP on PAD. Further details of 229 230 propensity score methods and stabilized IPTW analysis are described in the supplementary

231	appendix. For our primary outcome PAD, results were combined across the UKB and MGBB
232	using an inverse-variance weighted fixed effects meta-analysis, a two tailed association $P < 0.05$
233	determined statistical significance. In our secondary analysis of CHIP with 10 additional,
234	incident atherosclerotic diseases, a two-tailed Bonferroni p-value threshold of P<0.05/10=0.005
235	was used to declare statistical significance.
236	
237	Mice
238	Animal experiments followed protocols approved by the Institutional Ethics Committee
239	at the Centro Nacional de Investigaciones Cardiovasculares and conformed to EU Directive
240	86/609/EEC and Recommendation 2007/526/EC regarding the protection of animals used for
241	experimental and other scientific purposes, enforced in Spanish law under Real Decreto
242	1201/2005. All mice were maintained on a 12-h light/dark schedule in a specific pathogen-free
243	animal facility in individually ventilated cages and given food and water ad libitum. C57Bl/6J
244	Trp53-/- mice were obtained from the Jackson Laboratory. Ldlr-/- mice carrying the CD45.1
245	isoform of the CD45 hematopoietic antigen were generated by crossing LDLR-KO mice from
246	the Jackson Laboratory and B6.SJL-PtprcaPepcb/BoyCrl mice from Charles River Laboratories.
247	Competitive bone marrow transplantation and atherosclerosis induction in mice
248	CD45.1+ Ldlr-/- recipients were transplanted with suspensions of BM cells containing 20%
249	CD45.2+ <i>Trp53-/-</i> cells and 80% CD45.1+ <i>Trp53+/+</i> cells (20% KO-BMT mice) or 20 %
250	CD45.2+ <i>Trp53</i> +/+ cells and 80% CD45.1+ <i>Trp53</i> +/+ cells (20% WT-BMT mice) similar to
251	previous studies ¹⁷ (Figure II in the supplement). BM cells were isolated from femurs and tibias
252	of donor mice after euthanasia. Recipient Ldlr-/- mice were exposed to two doses of 450 rad
253	three hours apart. After the second irradiation, each recipient mouse was injected

with 10⁷ BM cells i.v. Water was supplemented with antibiotics for 7 days before transplant and
for 14 days post-transplant. Mice that did not recover full pre-irradiation body weight 28 days
after transplant were excluded from further analysis. Starting four weeks after BMT, mice were
fed a high fat high cholesterol (HF/HC) Western diet (Harlan-Teklad, TD.88137, Adjusted
Calories Diet; 42% from fat, 0.2% cholesterol) to promote hypercholesterolemia and the
development of atherosclerosis. Mice were maintained on a HF/HC diet for 9 weeks

260

261 *Quantification of aortic atherosclerosis burden in mice*

262 Mice were euthanized and aortas were removed after in situ perfusion with phosphate-buffered 263 saline injected through the left ventricle of the heart. Tissue fixation was achieved by immersion 264 in 4% paraformaldehyde in PBS overnight at 4°C. Aortic tissue was then dehydrated and 265 embedded in paraffin for sectioning. Histological sections comprising the aortic root as 266 determined by the location of the aortic valve leaflets were cut at a thickness of 4 μ m or 6 μ m. 267 An operator who was blinded to genotype quantified plaque size in a ortic root sections by 268 computer-assisted morphometric analysis of microscopy images. For each mouse, atherosclerotic 269 plaque size in a rtic root cross-sections was calculated as the average of 5 independent sections 270 separated by $\sim 16 \mu m$. Atherosclerotic plaque composition was examined by 271 immunohistochemical techniques. Vascular smooth muscle cells were identified with an alkaline 272 phosphatase-conjugated mouse anti-smooth muscle α -actin (SMA) monoclonal antibody (clone 273 1A4, SIGMA) and Vector Red Alkaline Phosphatase Substrate (Vector Laboratories). 274 Macrophages were detected with a rabbit anti-Mac2 monoclonal antibody (Santa Cruz 275 Biotechnologies), a biotin-conjugated goat anti-rat secondary antibody and streptavidin-HRP, 276 DAB substrate (all from Vector Laboratories), with hematoxylin counterstaining. Collagen

277 content was determined by a modified Masson's trichrome staining. Microscopy images were 278 analyzed using ImageJ software using the Color Deconvolution plugin. Plasma was collected in 279 EDTA-coated tubes and cholesterol levels were determined using an enzymatic assay 280 (Cholesterol E, WAKO Diagnostics). 281 282 Flow cytometry analyses of blood and tissue samples. 283 Peripheral blood was obtained from the facial vein and collected into EDTA-coated tubes. Bone 284 marrow cells were flushed out of two femurs and two tibias per mouse. Aortic arches were 285 digested for 45 minutes at 37°C in RPMI containing 10% FBS and 0.25 mg/ml Liberase TM

286 (Roche Life Science). Red blood cells were lysed in all samples by treatment with 1X Red Blood

287 Cell Lysis Buffer (eBioscience ThermoFisher) for 5 minutes on ice. Bone Marrow lineage-

negative cells were defined as negative for CD11b, Gr-1, Ter119, B220, CD3e and CD127. Bone

289 marrow HSPCs were defined as Lineage-, c-Kit+, Sca1+. Blood classical monocytes were

identified as CD45+, CD115^{Hi}, CD43^{Lo}, Ly6c^{Hi}; patrolling monocytes, as CD45+, CD115^{Hi},

291 CD43^{Hi}, Ly6c^{Lo}; neutrophils, as CD45+, CD115^{Int}, Ly6g+; T lymphocytes, as CD45+, CD115-,

B220-, CD3+; B lymphocytes, as CD45+, CD115-, CD3-, B220+; and aortic macrophages, as

293 CD45+, CD3-, Ly6g-, CD11B+, F4/80Hi. Gating strategies can be found in our previous

294 publications^{17, 18}. Samples were stained with combinations of biotinylated and/or fluorescently

295 labeled antibodies in PBS with 1% FBS for 30 min on ice. The following fluorescent antibodies

were used for staining and flow cytometry analysis: eFluor450-conjugated anti-CD45.2, FITC-

297 conjugated anti-CD45.2, Pe-Cy7-conjugated anti-CD45.1, FITC-conjugated anti-CD11b,

eFluor450-conjugated anti-CD11B, PE-conjugated anti-CD115, PE-eFluor610-conjugated anti-

299 CD3, FITC-conjugated anti-CD4 (from eBioscience); APC-Cy7-conjugated anti- B220, PerCP-

300	Cy5.5-conjugated anti-Ly6G, BV510-conjugated anti-Ly6G, BV711-conjugated anti-CD43, PE-
301	Cy7-conjugated anti-c-Kit, AlexaFluor647-conjugated anti-Sca-1 (from BD Biosciences); PE-
302	conjugated anti-F4/80 (from R&D Systems); PerCP-Cy5.5-conjugated anti-CD45.1, BV510-
303	conjugated anti-CD8a, PerCP-Cy5.5-conjugated anti-mouse Ki-67 (from BioLegend).
304	Fixation/permeabilization for Ki-67 intracellular staining was achieved using commercially
305	available kits following manufacturer's instructions (Foxp3 Transcription Factor Staining Buffer
306	Set, eBioscience ThermoFisher). Dead cells were excluded from analysis by DAPI staining in
307	unfixed samples and by LIVE/DEAD Fixable Near-IR staining (ThermoFisher Scientific) in
308	fixed samples. BD LSRFortessa and BD FACSymphony Cytometers (BD Bioscience) were used
309	for data acquisition. Data were analyzed with FlowJo Software.
310	
311	Murine macrophage culture and cell cycle analysis
312	Bone marrow-derived macrophages (BMDM) were obtained from suspensions of femoral BM
313	and differentiated for 7 days in the presence of RPMI Medium supplemented with antibiotics,
314	10% fetal bovine serum and 100 ng/ml MCSF. For cell-cycle analysis, MCSF concentration in
315	cell culture medium was decreased to 5 ng/ml for 48h to induce progressive synchronization of
316	macrophages in G0 phase (i.e. quiescence) and cell cycle re-entry was induced by treatment with
317	100 ng/ml MCSF. Macrophages were trypsinized and collected by centrifugation for 5 minutes at
318	300g. After fixation in 80% ethanol for 1 h at -20°C, cells were incubated for at least 30 minutes
210	with 50 water I manifium indide containing 0.25 mater I DNA as A (both from SICMA)

Labelled cells were analyzed in a BD LSRFortessa flow cytometer BD Bioscience and DNA

histograms were fitted into cell cycle distributions using ModFit 3.0 software (Verity Software

320

321

322

House).

2	2	2
•	Z	•

324 *Gene expression analysis by quantitative real-time PCR (qPCR) and Western Blot.*

325 326 Total RNA from aortic arch tissue was isolated using Trizol reagent and RNeasy kits (QIAGEN). 327 RNA (1 µg) was reverse transcribed with High-Capacity cDNA Reverse Transcription Kit 328 (Applied Biosystems) and qPCR was performed with SYBR® Green PCR Master Mix (Applied 329 Biosystems) in a AB7900 Real time PCR system. Results were analyzed with the $\Delta\Delta$ Ct method. 330 The average of 36B4 and β -actin was used as reference for normalization. Primer sequences can be found in our previous publication¹⁷. For Western Blot analysis of protein levels, protein 331 332 extracts from cultured macrophages were obtained using ice-cold lysis buffer (20mM Tris-HCl 333 pH 7.5, 150 mM NaC, 1 mM NA2EDTA, 1 mM EGTA, 1% Triton) supplemented with protease 334 and phosphatase inhibitors (Roche Applied Science). Equal amounts of protein lysates were 335 resolved by SDS-PAGE and the following antibodies were used for immunoblotting: anti-p53 336 (Cell Signaling, #32532S, dil 1/1000) and HRP anti-alpha tubulin (AbCam, #ab40742, dil 337 1/2000). An ImageQuant LAS 4000 biomolecular imaging system (GE Healthcare) was used for 338 image acquisition and the ImageJ software was used for band densitometric analysis. 339 340 *Statistical analysis of data in experimental studies* 341 Data are shown as mean \pm SEM unless otherwise stated. Statistical significance of differences in 342 experiments with two groups and only one variable was assessed by unpaired Student's t tests 343 (with Welch correction for unequal variance when appropriate) or Mann-Whitney U Tests.

344 Differences in experiments with more than one independent variable were evaluated by two-way

analysis of variance (ANOVA) with post-hoc Sidak's multiple comparison tests. All statistical

346 tests were performed using GraphPad Prism software (GraphPad Software Inc.).

348 **Results**

349 Study Cohorts and Risk Of Hematologic Malignancy

350 After excluding individuals with a known history of hematologic malignancy at enrollment, we

- 351 identified 37,657 unrelated individuals from the UKB and 12,465 individuals from MGBB with
- 352 whole exome sequencing data available for downstream analysis. Using a previously validated

353 somatic variant detection algorithm¹⁰, we identified 2,194 (5.8%) and 657 (5.4%) CHIP carriers

in the UKB and MGBB, respectively (Table III in the supplement). Demographic and clinical

355 characteristics of these individuals, stratified by CHIP status, are depicted in Table IV in the

supplement. CHIP carriers tended to be older, male, previous smokers, and have a history of

357 coronary artery disease, hypertension, and hyperlipidemia (two-tailed chi-squared and Wilcoxon-

358 rank sum P< 0.05).

359 We first replicated known CHIP associations¹⁰ with white blood cell (Beta 0.09 SD; 95%

360 CI 0.05-0.13; P=1.6x10⁻⁵), monocyte (Beta 0.05 SD; 95% CI 0.01-0.09; P=0.009), neutrophil

361 (Beta 0.10 SD; 95% CI 0.06-0.14; P=2.1x10⁻⁶), and platelet counts (Beta 0.07 SD; 95% CI 0.03-

362 0.11; P=0.0005) in UKB, with larger CHIP clone size as measured by variant allele fraction

363 (VAF) having stronger effects on blood counts (Figure III in the supplement). Consistent with

the existing literature^{5, 10}, CHIP also associated with incident hematologic malignancy (HR 2.20;

365 95% CI 1.70-2.85; P=1.8x10⁻⁹) - specifically for acute myeloid leukemia (HR 8.08; 95% CI

366 4.36-14.97; P=3.2x10⁻¹¹), myeloproliferative neoplasms (HR 5.89; 95% CI 3.69-9.89; P=9.7x10⁻

 14), and polycythemia vera (HR 12.37; 95% CI 4.85-31.54; P=1.4x10⁻⁷). This risk increased with

- 368 larger VAF (Figure IV in the Supplement).
- 369

370 CHIP and Incident PAD Risk

371 We next tested the association of CHIP status with incident PAD. Using available electronic 372 health record (EHR) data and a previously validated PAD definition¹³, we identified 338 and 419 373 incident PAD cases in UKB and MGBB, respectively. CHIP associated with a 58% increased 374 risk of incident PAD in the UKB ($HR_{UKB} = 1.58, 95\%$ CI: 1.11-2.25; P=0.01, Figure 1), results 375 that were replicated in MGBB (Overall HR = 1.66, 95% CI: 1.31-2.11; P= 2.4×10^{-5}). We then 376 sought to evaluate whether those with larger CHIP clone sizes (i.e., higher VAF) had greater risk 377 for PAD, as larger CHIP clones associate more strongly with adverse clinical outcomes⁶. We observed a graded relationship between CHIP VAF and PAD, as those with a VAF > 10% had 378 379 even greater risk for an incident PAD event (Overall HR = 1.97, 95% CI: 1.44-2.71; P= $2.3\times10^{-5},$ 380 Figure 1). Additional sensitivity analyses, including propensity score adjustment and a marginal 381 structural Cox proportional hazards model estimated through stabilized inverse-probability-382 treatment-weight revealed similar results in the UKB (Figure V in the supplement). Subsequent 383 analyses showed no significant interaction between CHIP status and either age, sex, or smoking 384 status on incident PAD risk. 385

386 CHIP and Incident Atherosclerosis Across Multiple Vascular Beds

We next assessed whether CHIP was associated with 9 other incident atherosclerotic diseases across multiple vascular beds. Using EHR-based disease definitions¹⁹, we tested the association of CHIP with atherosclerotic disease across the mesenteric (acute and chronic), coronary, and cerebral vascular beds, as well as with aneurysmal disease (aortic and any other aneurysm). We observed significant associations for coronary artery disease (HR 1.40, 95% CI: 1.20 to 1.63; P=1.9x10⁻⁵), any aortic aneurysm (HR 1.74; 95% CI: 1.21 to 2.51; P=0.0028), other aneurysms (HR 1.70; 95% CI: 1.23 to 2.34; P=0.0013), and chronic mesenteric ischemia (HR

394	9.12; 95% CI: 2.34 to 35.63; P=0.0015) across both cohorts, with directionally consistent effect
395	estimates observed for all the tested phenotypes (Figure 2a). These associations were
396	consistently stronger for large CHIP clones (Figure VI in the supplement). We then created a
397	composite, incident atherosclerosis outcome combining all nine atherosclerotic phenotypes
398	("pan-arterial atherosclerosis", Table V in the Supplement). CHIP associated with this
399	combined incident pan-arterial atherosclerosis endpoint (HR 1.31, 95% CI: 1.14 to 1.49,
400	P=9.7x10 ⁻⁵), again with stronger effects conferred by large CHIP clones (HR 1.45; 95% CI: 1.20
401	to 1.75; P=0.00013) (Figure 2b,c).
402	
403	Gene-specific analyses of CHIP with incident atherosclerotic diseases
404	Next, we sought to understand whether the clonal hematopoiesis putative driver gene
405	differentially affected the risk of acquiring atherosclerosis. Previous work has focused primarily
406	on the epigenetic regulators DNMT3A and TET2 ^{3, 17} , and whether DDR CHIP confers an
407	increased risk of atherosclerosis is unknown. We stratified the CHIP-PAD and CHIP pan-arterial
408	atherosclerosis analyses by putative driver genes and specific mutations - focusing on DNMT3A,
409	TET2, ASXL1, JAK2, the DDR genes PPM1D and TP53, and mutations that specifically disrupt
410	splicing factor genes (LUC7L2, PRPF8, SF3B1, SRSF2, U2AF1, and ZRSR2) ²⁰ . We observed an
411	association of CHIP with PAD across the four common CHIP genes (DNMT3A, TET2, ASXL1,
412	and JAK2), with significant heterogeneity of incident PAD effect sizes across the CHIP genes
413	$(P_{heterogeneity} = 0.03)$ (Figure 3a). This heterogeneity persisted in sensitivity analysis after
414	excluding $JAK2$ carriers (P _{heterogeneity} = 0.046). These data also revealed the novel finding that
415	DDR TP53 and PPM1D CHIP associates with incident PAD (HR 2.72; 95% CI: 1.20 to 1.75;
416	P=0.00013) and incident CAD (HR 2.51; 95% CI: 1.52-4.14; P=0.00032), with a stronger effect

417	on PAD conferred by TP53 (HR 4.98; 95% CI: 1.23-20.09; P=0.024, Figure 3a-c). Similar
418	findings were observed for the incident pan-arterial atherosclerosis outcome when stratifying by
419	putative driver gene (Figure VII in the supplement). Further sensitivity analysis for DDR-
420	CHIP and incident PAD when excluding solid organ malignancy did not significantly change the
421	associations ($P_{heterogeneity} > 0.05$).
422	
423	Atherosclerosis development in p53-/ CHIP mice

424 Based on our gene specific findings, we next further characterized the effects of reduced function 425 of hematopoietic p53 in atherosclerotic mice. To mimic CHIP and test whether the expansion of 426 p53-deficient hematopoietic cells contributes to atherosclerosis, a competitive bone marrow 427 transplantation (BMT) strategy was used to generate atherosclerosis-prone Ldlr-/- chimeric mice 428 carrying 20% Trp53-/- hematopoietic cells (20% KO-BMT mice). These mice then consumed a 429 high fat/high cholesterol diet for 9 weeks to induce atherosclerosis development. To distinguish 430 donor Trp53-/- and Trp53+/+ cells in this experimental setting, Trp53+/+ cells were obtained 431 from mice carrying the CD45.1 variant of the CD45 hematopoietic antigen, whereas Trp53-/-432 cells were obtained from mice carrying the CD45.2 variant of this protein. Control mice (20% 433 WT-BMT) were transplanted with 20% CD45.2+ Trp53+/+ cells and 80% CD45.1+ Trp53+/+ 434 cells (Figure 4a and Figure II in the supplement). Flow cytometry analysis of CD45.2+ blood 435 cells established that this BMT strategy led to a modest, but significant expansion of donor 436 *Trp53-/-* BM-derived cells compared to *Trp53+/+* cells in both BM hematopoietic 437 stem/progenitor cells (HSPCs) and circulating white blood cells (Figure 4B,C), consistent with previous studies²¹⁻²³. Transplanted *Trp53-/-* BM cells expanded into all blood cell lineages to a 438 439 similar extent, but this relative expansion did not affect absolute blood cell counts (Figure VIII

440 in the supplement). Having validated this mouse model of p53 CHIP based on a competitive 441 BMT strategy, we next assessed whether this phenomenon affects the development of 442 atherosclerosis or related metabolic abnormalities. The presence and expansion of Trp53-/- cells 443 led to a significant $\sim 40\%$ increase in plaque size in the aortic root of male *Ldlr*-/- mice (Figure 444 4D), without affecting body weight, spleen weight or serum cholesterol levels (Figure VIII in 445 the supplement, C-E). Similar results were obtained in female *Ldlr-/-* mice (Figure IX in the 446 supplement). In contrast to previous work on DNMT3A/TET2 CHIP, the expansion of p53deficient cells^{12, 17, 18, 24, 25} did not affect the expression of the pro-inflammatory cytokines IL-6 447 448 and IL-1 β in the atherosclerotic aortic wall (Figure X in the supplement). 449 450 Proliferation and expansion of p53-deficient macrophages in the murine atherosclerotic aorta 451 Increased atherogenesis in mice carrying *Trp53-/-* cells was paralleled by a substantial increase 452 in plague macrophage content, as assessed by immunohistological staining of Mac2, with no 453 significant changes in other cell components (Figure 5A), suggesting a contribution of increased 454 arterial macrophage burden to accelerated atherosclerosis in conditions of p53 CHIP. Flow 455 cytometry analysis of matched samples from blood and digested atherosclerotic aortae from 456 20% KO-BMT mice revealed substantially higher chimerism in a rtic macrophages ($\sim 76\%$ 457 *Trp53-/-*) than in blood classical monocytes (\sim 48%), the major source of plaque macrophages 458 (Figure 5B). This expansion of p53-deficient macrophages within the vascular wall was 459 paralleled by a 2-fold increase in the frequency of proliferating cells within the CD45.2+ Trp53-460 /- aortic macrophage population compared to CD45.2+ *Trp53*+/+ macrophages, as assessed by 461 flow cytometry analysis of the proliferation-related antigen Ki-67 (Figure 5C). Consistent with 462 our observations in vivo, cultured Trp53-/- macrophages exhibit accelerated mitotic cell cycle

463	progression, with a >2-fold increase in the percentage of S-phase cells upon stimulation with
464	macrophage colony stimulating factor (MCSF), a major determinant of plaque macrophage
465	proliferation ²⁶ (Figure 5D). <i>Trp53</i> expression analysis suggests a central role of p53 in the
466	normal regulation of macrophage cell cycle progression, as p53 was expressed in quiescent
467	macrophages at the transcript and protein level and further induced after MCSF stimulation
468	(Figure 5E,F). Furthermore, p53-deficient macrophages exhibited major changes in the
469	expression of pivotal regulators of cell cycle entry and progression, such as Cdkn1a/p21 ^{Cip1} and
470	Cyclin B1 (Figure 5G).

471

472 **Discussion**

473 This study combined exome sequencing data across two biobanks to detect somatic 474 mutations in over 50,000 individuals and observed that the presence of CHIP was significantly 475 associated with an increased risk of developing PAD and atherosclerosis across multiple arterial 476 beds. Increased risk was differentially observed across CHIP driver genes with evidence of a 477 graded relationship with CHIP VAF, with large CHIP clones conferring greater risk of disease. 478 Lastly, analysis of p53 CHIP using a BMT murine model showed increased aortic atherosclerotic 479 plaque among p53 CHIP carriers accompanied by expansion of plaque macrophages, supporting 480 a direct contribution of p53-mutant hematopoietic cells to accelerated atherogenesis.

These findings permit several conclusions. First, in humans, CHIP appears to promote atherosclerosis across the entire arterial system. Previous work linked CHIP with increased risk of coronary artery disease and early-onset MI^{2, 3}. We build on these findings by demonstrating that CHIP is also associated with PAD, and a composite pan-arterial atherosclerosis outcome reflective of an increased burden of atherosclerosis throughout the human arterial system. In

addition, we observed suggestive CHIP associations with aneurysmal degeneration of the aorta.
The genetic and epidemiologic risk factors underlying atherosclerotic occlusive disease and
AAA overlap considerably²⁷, and substantial evidence implicates inflammation and macrophage
infiltration in driving this aortic disease²⁸. The observed link between CHIP and aneurysmal
disease warrants further investigation in future studies.

491 Second, DDR gene CHIP appears to confer an increased risk of atherosclerotic 492 cardiovascular disease. In previous work, Jaiswal et al demonstrated an increased risk of 493 coronary artery disease among individuals with CHIP through DNMT3A, TET2, ASXL1, and 494 JAK2 somatic driver mutations³. DDR CHIP is often observed among individuals following 495 cytotoxic chemotherapy for the treatment of malignancy and has been linked to the development 496 of therapy-related myeloid neoplasms, but limited evidence is available to inform clinical 497 decision making regarding whether DDR CHIP carriers have increased risk of cardiovascular 498 disease. The current study demonstrates that CHIP related to DDR-genes (TP53, PPM1D) 499 confers an increased risk of developing atherosclerosis. These findings lend human genetic 500 support to the concept that post-cytotoxic chemotherapy patients may benefit from surveillance 501 for atherosclerotic conditions in addition to therapy-related myeloid neoplasms. 502 Third, CHIP related to TP53 mutations appears to drive atherosclerosis risk via expansion

of p53-deficient macrophages in occlusive plaque lesions. Previous experimental studies assessed the role of p53 in atherogenesis using mice engineered to exhibit gain or loss of function of p53 in the whole body or in specific cell types, with a variety of results²⁹⁻³⁵. Here we demonstrate that carrying a fraction of p53-deficient blood cells is sufficient to accelerate atherosclerosis development, as these cells have a selective advantage to expand, both in HSPCs within the BM and in macrophages within the arterial wall, leading to increased macrophage

509 burden in the atherosclerotic plaque. Mechanistically, p53-deficient macrophage expansion 510 seems related to increased proliferation, a major driver of macrophage burden in atherosclerotic 511 plaques³⁶. Although p53 expression is typically induced by DNA damage or other kinds of 512 cellular stress, we found that it is expressed in resting conditions in cultured macrophages and 513 further induced by mitogenic stimulation, suggesting a physiological role in the regulation of 514 macrophage cell cycle progression. Accordingly, p53-deficient macrophages exhibited 515 accelerated cell cycle kinetics. Overall, these experimental findings provide support to the notion 516 that TP53 CHIP mutations contribute directly to accelerated atherosclerosis and highlight major 517 differences in the mechanisms underlying accelerated atherosclerosis in CHIP driven by 518 mutations in TP53 or epigenetic regulators. Previous murine studies on Tet2 CHIP showed that 519 TET2-deficient cells expand in bone marrow and blood, but not in the atherosclerotic plaque. In 520 contrast, we found that p53 exhibits a double competitive advantage, expanding in both the BM 521 and arterial wall, which suggests that small TP53-mutant blood clones may be sufficient to 522 accelerate atherosclerosis development. Evaluating this possibility will require additional studies 523 using high sensitivity sequencing strategies. Furthermore, in contrast to previous reports related to DNMT3A/TET2 CHIP^{12, 17, 18, 24, 25}, we did not observe a significant effect of p53 deficiency on 524 525 the expression of the pro-inflammatory cytokines IL-1ß and IL-6. These results are consistent 526 with previous human data showing that circulating levels of pro-inflammatory cytokines are 527 significantly increased in carriers of CHIP driven by mutations in these epigenetic regulators, but 528 not in carriers of mutations in TP53 or PPM1D¹⁰. These mechanistic differences between TP53-529 CHIP and *DNMT3A/TET2*-CHIP require consideration when designing preventive care strategies 530 targeting the effects of CHIP on atherosclerosis. Thus, while the pathogenic effects of TET2-531 CHIP may be prevented by targeting IL-1 β -driven inflammation¹⁷, accelerated atherosclerosis

associated with *TP53* mutations may be better tackled by other strategies. Additional
experimental and clinical studies should evaluate these opportunities for personalized medicine
in the context of CHIP.

Lastly, a recent publication has generated a novel hypothesis regarding the relationship between CHIP and atherosclerosis³⁷. In their analysis, Heyde et al. suggest that CHIP may be a symptom of the atherosclerosis trait complex (the interplay of chronic inflammation,

538 hyperlipidemia, and arterial plaque), rather than a causal risk factor, based on murine and human 539 observations that atherosclerosis may accelerate HSC proliferation and somatic evolution. While 540 their study engenders an intriguing hypothesis, there are several observations in the literature and 541 in our current study that we believe do not support this interpretation. Firstly, in the Heyde et al. 542 study, Ldlr-null mice irradiated and transplanted with bone marrow of Tet2 -/- mice that were fed 543 an atherogenic diet demonstrated greater Tet2 -/- neutrophil and monocyte expansion than 544 similar mice fed normal chow. However, in marked contrast, we previously showed that Tet2-/-545 cells expand similarly when *Ldlr*-null mice are fed either a high cholesterol diet or normal 546 chow¹⁷. Furthermore, in our prior work, the expansion of *Tet2-/-* cells was completely unaffected 547 by treatment with a pharmacological NLRP3 inhibitor, even though this inhibitor led to a 2-fold 548 decrease in atherosclerotic plaque size¹⁷. Secondly, in our current analysis of the pan-arterial 549 atherosclerosis endpoint, CHIP was associated with incident atherosclerotic events among a pool 550 of individuals without any history of atherosclerosis at baseline - suggesting that CHIP precedes 551 clinically significant occlusive disease. Thirdly, Heyde et al. state that the uniform hazard ratios 552 observed for the CHIP-coronary artery disease association provide supportive evidence for the 553 notion that atherosclerotic disease precedes the development of clonal hematopoiesis. However, 554 in our study we identify significant heterogeneity of incident PAD effect sizes when stratifying

555 by CHIP genes, as well as a dose-response relationship between CHIP clone size (or VAF) and 556 incidence of atherosclerosis, suggesting that CHIP genes vary in their effect on incident PAD 557 risk, and that expanded CHIP variants have a stronger influence on future atherosclerotic risk. 558 Thus, given the 1) association with incident atherosclerotic disease, 2) dose-response relationship with CHIP clone size and heterogeneity by CHIP gene, and 3) that TP53, TET2, and JAK2³⁸ 559 560 appear to drive atherosclerosis through disparate mechanisms, clonal hematopoiesis acting as a 561 causal risk factor appears to be a more parsimonious explanation to unify these findings. 562 Several limitations merit mention. First, our PAD and cardiovascular disease phenotypes 563 are based on EHR data and may result in misclassification of case status. Such misclassification 564 would likely reduce statistical power for discovery and on average bias results toward the null. 565 Second, selection bias from differential loss-of-follow up, volunteer bias, and missingness in 566 covariates may be present given the nature of the genetic biobanks used in this study. Third, 567 while we maximized the number of participants in our analysis of CHIP and additional 568 atherosclerotic diseases, it may still have been underpowered for certain phenotypes. Lastly, the 569 cohorts in these studies are largely of European ancestry; while prior reports have not observed significant phenotypic differences in CHIP associations by ancestry^{5, 12}, further epidemiological 570 571 studies in ethnically diverse individuals are required to ensure that this is the case for PAD as 572 well.

In conclusion, CHIP is associated with incident atherosclerosis in multiple vascular beds, with murine evidence of increased plaque among *TP53* CHIP carriers through an expansion of plaque macrophages (**Figure 6**). The observations presented here expand insight into CHIPmediated atherosclerosis. The novel finding that DDR gene CHIP plays a particular role in PAD raises new questions regarding the mechanisms of regional heterogeneity of atherosclerotic

- 578 involvement in face of systemic exposure to traditional risk factors such as dyslipidemia,
- 579 hypertension, and smoking.



611
612 Figure 1. CHIP and incident PAD risk. a) Association of CHIP and large CHIP (VAF>10%)
613 carrier state with incident PAD events in the UK Biobank (UKB) and Mass General Brigham
614 Biobank (MGBB). Results were combined using an inverse-variance weighted fixed effects
615 meta-analysis. b) Cumulative proportion of individuals developing PAD stratified by CHIP VAF
616 clone size category in the UK Biobank. c) Fraction of individuals developing incident PAD by
617 CHIP VAF in the UK Biobank. CHIP = clonal hematopoiesis of indeterminate potential; VAF =

- 618 variant allele fraction; PAD = peripheral artery disease

а.	Association of CHIP with Incident Disease	HR	95% CI	Р	Cases (N)	Controls (N)	Cases with CHIP (N)	Controls with CHIP (N)
Peripheral artery disease UK Biobank MGB Biobank Overall		1.58 1.74 1.67	[1.11; 2.25] [1.26; 2.39] [1.32; 2.11]	0.01 0.00068 2.2e–05	302 373	37,106 11,875	36 46	2,143 596
Coronary artery disease UK Biobank MGB Biobank Overall		1.36 1.44 1.40	[1.10; 1.68] [1.15; 1.80] [1.20; 1.63]	0.0039 0.0015 1.9e-05	1,044 858	35,564 11,178	98 89	2,019 525
Any aortic aneurysm UK Biobank MGB Biobank Overall		1.90 1.27 1.74	[1.26; 2.85] [0.57; 2.81] [1.21; 2.51]	0.0022 0.56 0.0028	194 78	37,433 12,127	27 7	2,163 617
Abdominal aortic aneurysm UK Biobank MGB Biobank Overall		1.78 2.03 1.83	[1.05; 3.03] [0.77; 5.37] [1.15; 2.92]	0.034 0.15 0.011	113 36	37,528 12,346	16 5	2,175 640
Other aneurysm UK Biobank MGB Biobank ← Overall		1.93 1.07 1.70	[1.34; 2.78] [0.54; 2.13] [1.23; 2.34]	0.0004 0.85 0.0013	244 132	37,369 11,943	34 9	2,155 600
Chronic mesenteric ischemia MGB Biobank Overall		9.12 9.12	[2.34; 35.63] [2.34; 35.63]	0.0015 0.0015	12	12,424	4	650
Acute mesenteric ischemia UK Biobank Overall		2.31 2.31	[1.07; 4.97] [1.07; 4.97]	0.032 0.032	49	37,598	8	2,186
Atherosclerosis of renal artery MGB Biobank Overall		1.93 1.93	[0.55; 6.79] [0.55; 6.79]	0.3 0.3	25	12,392	3	647
Cerebral atherosclerosis UK Biobank MGB Biobank Overall		0.90 1.79 1.20	[0.67; 1.22] [1.25; 2.57] [0.95; 1.52]	0.51 0.0015 0.12	623 269	36,850 11,990	45 37	2,143 598
Pan-arterial atherosclerosis UK Biobank MGB Biobank Overall		1.33 1.19 1.29	[1.14; 1.56] [0.93; 1.51] [1.13; 1.47]	0.0003 0.17 0.00015	1,875 977	34,366 10,488	178 76	1,920 472
0.8			_			_		
b. Pa	an-arterial atherosc	lerosi	s	c.		Pa	in-arterial ather	osclerosis
U0.075		فمرم	_					
ative Propo		a service and				0.15 thero doind		
0.025-	- A Carrier					tion Devel I-Arterial J		
0.000 - 0	5 Yooro		10			ча 0.10-		



Figure 2. CHIP and incident pan-arterial atherosclerosis risk. a) Association of CHIP with 9

492

21910

10

0.05

or

0,0

- 628 incident atherosclerotic diseases separately and combined in a 'Pan-arterial atherosclerosis'
- 629 phenotype in the UKB, MGBB, and meta-analyzed across both studies ("Overall"). b)
- 630 Cumulative risk of incident atherosclerosis across the composite 'pan-arterial atherosclerosis'
- 631 phenotype stratified by no CHIP, small CHIP (VAF<10%), and large CHIP (VAF≥10%) carrier
- 632 state in the UK Biobank. c) Association of CHIP VAF with fraction of individuals developing
- 633 pan-arterial atherosclerosis in the UK Biobank. CHIP = clonal hematopoiesis of indeterminate
- 634 potential; VAF = variant allele fraction; PAD = peripheral artery disease

992 1448 40899

> 5 Years

Number at risk

4179

CHIP

0,50

0.25

0.15



661 Figure 3: Gene-specific association of CHIP with incident peripheral artery disease (PAD). 662 a) CHIP-PAD association analyses stratified by putative CHIP driver gene. Results following meta-analysis across the UKB and MGBB are shown. b) Gene-specific comparison of HR and 663 95% CI for hematologic malignancy (x-axis) and PAD (y-axis) in the UKB. c) Association of 664 665 DDR CHIP (*PPM1D or TP53*) with incident peripheral artery disease, coronary artery disease, 666 and pan-vascular atherosclerosis. Results across UK Biobank and MGB Biobank were combined using an inverse-variance weighted fixed effects meta-analysis. CHIP = clonal hematopoiesis of 667 668 indeterminate potential; DDR = DNA-damage repair; VAF = variant allele fraction; PAD = 669 peripheral artery disease



670

671 Figure 4: Accelerated atherosclerosis in a murine model of *TP53* mutation-driven CHIP.

a) Summary of the competitive BMT approach and the timeline of these studies. 20% KO-BMT

673 male mice and 20% WT-BMT controls were fed a high-fat/high-cholesterol (HF/HC) diet for 9

674 weeks, starting 4 weeks after BMT (n=10 20% WT-BMT, n=7 20% KO-BMT, unless otherwise 675 noted). b) Percentage of CD45.2+ cells in the bone marrow HSPC population (Lin- Sca1+ cKit+

cells) after 9 weeks on HF/HC diet (13 weeks post-BMT), evaluated by flow cytometry (n= 5

677 20% WT-BMT, n=6 20% KO-BMT). c) Percentage of CD45.2+ in white blood cells, evaluated

by flow cytometry (**p<0.01, ***p<0.001). Representative CD45.1/CD45.2 dot plots are shown.

d) Aortic root plaque size. Representative images of hematoxylin and eosin-stained sections are

shown; atherosclerotic plaques are delineated by dashed lines. Scale bars, 100 μm.





682 Figure 5: Increased proliferation and expansion of p53-deficient macrophages. a) Plaque 683 composition in 20% KO BMT female mice (n=10) and controls (n=8) quantified as absolute 684 intimal content of macrophages (Mac2 antigen immunostaining), vascular smooth muscle cells 685 (smooth muscle α -actin, SMA immunostaining), collagen (Masson's trichrome staining) and 686 necrotic core (collagen-free acellular regions). Representative images of Mac2- and collagen-687 stained histological sections of 20% KO BMT mice are shown. b) Percentage of CD45.2+ cells 688 within the aortic macrophage population (CD3-, Ly6g-, CD11B+, F4/80^{Hi}, n = 3 pools of two aortic arches per BM genotype) and blood classical monocytes (CD3-, CD115^{Hi}, Ly6g-, CD43^{Lo}, 689 690 Ly6c^{Hi}, n=6 per BM genotype) of 20% KO BMT mice and controls, evaluated by flow 691 cytometry. Representative CD45.1/CD45.2 plots of aortic macrophages are shown. c) Percentage 692 of Ki-67+ proliferating cells within the aortic CD45.2+ macrophage population of 20% KO 693 BMT mice and controls (n = 3 pools of two aortic arches per BM genotype), evaluated by flow 694 cytometry. Representative plots are shown. d) % of S-phase cells in cultures of Trp53-/- and +/+ 695 murine bone marrow-derived macrophages, evaluated by propidium iodide staining of cellular 696 DNA content and flow cytometry; treatment with MCSF was used to induce cell cycle entry and 697 progression in quiescent G0-synchronized macrophages (a representative experiment with 698 macrophages from n=3 mice per genotype is shown). e, f) qPCR (e) and Western Blot (f) 699 analyses of Trp53 expression in cultured macrophages after MCSF mitogenic stimulation. p53 700 protein levels were normalized to α -tubulin. A representative blot is shown. g) Expression of cell cycle regulators *Cdkn1a*/p21^{Cip1} and *Ccnb1*/Cyclin B1 in cultured *Trp53-/-* and +/+ macrophages 701 702 proliferating asynchronously (Async) or after MCSF stimulation. *p<0.05, **p<0.01,

703 ***p<0.001.



705

706

Figure 6. In this study, we assessed the association of clonal hematopoiesis of indeterminate 707 708 potential (CHIP) with myeloid driver mutations with pan-arterial atherosclerosis. CHIP is a 709 category of age-related somatic variants which are associated with incident leukemia and thought to be implicated in atherosclerosis primarily by altering macrophage function and promoting 710 711 thrombosis. CHIP clones can be characterized by the fraction of blood cells carrying the clone, 712 referred to as the variant allele fraction (VAF); here we categorized large CHIP clones as 713 variants with VAF>10%. Across 50,112 individuals from the UK Biobank and Mass-General 714 Brigham Biobank, we observed that CHIP is associated with increased risk of incident peripheral 715 and pan-arterial atherosclerosis, with stronger effects conferred by large CHIP clones (HR 1.5x). 716 In addition, we observed and a novel associations for TP53 and PPM1D CHIP (HR 2.0x). CHIP 717 was found to be individually associated with a variety of atherosclerotic conditions, with 718 Bonferroni-significant associations (double-starred, **) identified for peripheral artery disease 719 (PAD), coronary artery disease (CAD), aortic aneurysm, and chronic mesenteric ischemia. HR 720 for CHIP are displayed in blue and for large CHIP in purple. Functional analysis was performed 721 to further investigate the observed TP53-PAD association. Ldlr-KO 20% p53 -/- bone-marrow transplanted mice had a significant increase in plaque size, with significant expansion of p53-722 723 deficient macrophages in plaque (P<0.001) at 12 weeks. 724

725





773 Supplementary Figure II. Competitive bone marrow transplantation approach to generate a

774 murine model of p53 CHIP

775



reflect average counts across non-CHIP carriers. The vertical black dotted line reflects the cutoff

VAF for Large CHIP (VAF>0.1). CHIP = clonal hematopoiesis of indeterminate potential; VAF

818 819

820

= variant allele fraction



847 Associations are adjusted for age, age², sex, smoking status, Townsend deprivation index, and

848 the first ten principal components of genetic ancestry. CHIP = clonal hematopoiesis of

849 indeterminate potential; VAF = variant allele fraction



879 peripheral artery disease

Q	Q	1
0	0	L

o	0	\mathbf{r}
0	0	7

883 884	Association of Large CHIP with Incident Disease	HR	95% CI	Ρ	Cases (N)	Controls (N)	Cases with CHIP (N)	Controls with CHIP (N)
Peripheral artery disease UK Biobank MGB Biobank Overall		2.25 1.71 1.97	[1.45; 3.49] [1.09; 2.68] [1.44; 2.69]	0.00028 0.02 2.4e-05	302 373	37,106 11,875	22 21	879 287
Coronary artery disease UK Biobank MGB Biobank Overall		1.44 1.56 1.50	[1.06; 1.94] [1.14; 2.15] [1.20; 1.86]	0.018 0.0061 0.00031	1,044 858	35,564 11,178	45 41	833 249
Any aortic aneurysm UK Biobank MGB Biobank « Overall		2.24 1.19 2.00	[1.29; 3.88] [0.37; 3.85] [1.22; 3.29]	0.004 0.77 8.0063 885	194 78	37,433 12,127	14 3	895 293
Abdominal aortic aneurysm UK Biobank Overall		2.49 2.49	[1.29; 4.80] [1.29; 4.80]	0.0064 0.0064	113	37,528	10	900
Other aneurysm UK Biobank MGB Biobank <	·	2.46 1.29 2.14	[1.54; 3.95] [0.52; 3.18] [1.41; 3.26]	0.00018 0.58 0.00036	244 132	37,369 11,943	19 5	890 283
Chronic mesenteric ischemi MGB Biobank Overall		14.70 14.70	[3.34; 64.70] [3.34; 64.70] 886	0.00038 0.00038	12	12,424	3	310
Acute mesenteric ischemia UK Biobank Overall		1.91 1.91	[0.59; 6.24] [0.59; 6.24]	0.28 0.28	49	37,598	3	908
Cerebral atherosclerosis UK Biobank « MGB Biobank Overall	*	1.05 1.66 1.25	[0.69; 1.60] [0.98; 2.82] [0.90; 1.74]	0.82 0.062 0.18 88	623 269	36,850 11,990	23 15	886 288
Pan-arterial atherosclerosis UK Biobank MGB Biobank Overall		1.55 1.14 1.43	[1.25; 1.92] [0.79; 1.64] [1.19; 1.72]	5.9e–05 0.48 0.00013	1,875 977	34,366 10,488	89 32 888	780 223
889		,						

890

890

091

892 Supplementary Figure VI: Association of Large CHIP (VAF>10%) with incident pan-arterial

893 atherosclerosis, combined across peripheral artery disease, coronary artery disease, aneurysms,

894 chronic and acute mesenteric ischemia, cerebral atherosclerosis, and renal artery stenosis. CHIP

895 = clonal hematopoiesis of indeterminate potential; VAF = variant allele fraction

897										
8(a.						b.				
844		Association of CHIP with Incident Atherosclerosis	нв	95% CI	Р					
000	СНІВ						Association of Large CHIP with Incident Atherosclerosis	HR	95% CI	Р
201	UK Biobank	+	1.33	[1.14; 1.56]	0.0003	Large CHIP				
901	MGB Biobank		1.19	[0.93; 1.51]	0.17	UK Biobank		1.55	[1.25; 1.92]	5.9e-05
902	Overall	-	1.29	[1.13, 1.47]	0.00015	MGB Biobank	< <u>-</u>	1.14	[0.79; 1.64]	0.48
202	All Genes, Excluding JA	K2				Overall		1.43	[1.19, 1.72]	0.00013
903	UK Biobank MGB Biobank		1.29	[0.98; 1.71]	0.07	All Genes, Excluding J	AK2			
904	Overall		1.20	[1.03; 1.49]	0.022	UK Biobank MGB Biobank		1.54	[1.24; 1.91]	9.3e-05
201	DINETOA					Overall		1.43	[1.19; 1.72]	0.00016
905	UK Biobank		1.26	[1.03: 1.54]	0.022	DUNTOA				
906	MGB Biobank	<	0.94	[0.65; 1.36]	0.74	UK Biobank		1 43	[1.05 1.94]	0.023
200	Overall		1.18	[0.99; 1.41]	0.063	MGB Biobank	<	1.13	[0.68; 1.89]	0.63
907	TET2					Overall		1.34	[1.03; 1.75]	0.028
908	UK Biobank		1.66	[1.20; 2.29]	0.002	TET2				
200	MGB Biobank		1.74	[1.14; 2.66]	0.0098 5 7e-05	UK Biobank		1.95	[1.29; 2.94]	0.0015
909	Overall		1.03	[1.01, 2.10]	5.76-05	MGB Biobank	<	1.07	[0.48; 2.41]	0.86
910	ASXL1		4 00	[1 00 0 01]		Overall		1.72	[1.13, 2.43]	0.0007
210	UK Biobank MGB Biobank	*	1.62	[1.00; 2.61]	0.049	ASXL1				
911	Overall		1.43	[0.93; 2.20]	0.1	UK Biobank Overall		2.27	[1.39; 3.72] [1.39: 3.72]	0.0011
912	TREA					o fordin		2.27	[1.00, 0.72]	0.0011
)1 <u>2</u>	UK Biobank	<	1.32	[0.43; 4.10]	0.63	TP53 MCB Bisbank		1.00	[0 15: 7 70]	0.04
913	MGB Biobank		2.26	[0.84; 6.08]	0.11	Overall	< · · · · · · · · · · · · · · · · · · ·	1.08	[0.15; 7.70]	0.94
914	Overall		1.79	[0.85; 3.78]	0.12					
	PPM1D					PPM1D MGB Biobank		4 20	[1 54: 11 45]	0.005
915	UK Biobank	<	1.40	[0.45; 4.34]	0.56	Overall		4.20	[1.54; 11.45]	0.005
916	MGB BIODANK Overall		2.57	[1.14; 5.80] [1.08:4.05]	0.023					
210				[]		MGB Biobank		2 65	[1 09 6 43]	0.031
917	TP53 or PPM1D		4.04	[0.00.0.00]	0.40	Overall		2.65	[1.09; 6.43]	0.031
018	MGB Biobank		2.46	[0.60; 2.98]	0.48	LA KO				
710	Overall		1.95	[1.19; 3.20]	0.0084	UK Biobank	<	2.23	[0.56: 8.94]	0.26
919	IAK2					Overall	· · · · · · · · · · · · · · · · · · ·	2.23	[0.56; 8.94]	0.26
920	UK Biobank	<	2.23	[0.56; 8.94]	0.26			`		
20	Overall	· · · · · · · · · · · · · · · · · · ·	2.23	[0.56; 8.94]	0.26		HR			
921	(081 2 4 810)							
922	· · · · · · · · · · · · · · · · · · ·	HR								
) <u></u>										
923										
924										

Supplementary Figure VII: Association of a) CHIP and b) Large CHIP genes with incident
 pan-arterial atherosclerosis, combined across peripheral artery disease, coronary artery disease,
 aneurysms, chronic and acute mesenteric ischemia, cerebral atherosclerosis, and renal artery
 stenosis. CHIP = clonal hematopoiesis of indeterminate potential; VAF = variant allele fraction

929



933 934

Supplementary Figure VIII: 20% KO-BMT male mice and 20% WT-BMT controls were fed a
high-fat/high-cholesterol (HF/HC) diet for 9 weeks, starting 4 weeks after BMT. a) Percentage of
CD45.2+ cells in different white blood cell (WBC) lineages in peripheral blood, evaluated by
flow cytometry (***p<0.001). b) Absolute counts of main WBC sub-populations in peripheral
blood, evaluated by flow cytometry. c) Body weight. d) Spleen weight. e) Total cholesterol level

940 in serum, evaluated by enzymatic methods.

- 941
- 942
- 943



944 945

Supplementary Figure IX. 20% KO-BMT female mice (n=13) and 20% WT-BMT controls
(n=17) were fed a high-fat/high-cholesterol (HF/HC) diet for 9 weeks, starting 4 weeks after
BMT. a) Percentage of CD45.2+ in white blood cells at different timepoints, evaluated by flow
cytometry (***p<0.001). b) Percentage of CD45.2+ cells in different white blood cell (WBC)
lineages in peripheral blood after 9 weeks on HF/HC diet (13 weeks post-BMT), evaluated by
flow cytometry (***p<0.001). c) Aortic root plaque size. Representative images of hematoxylin
and eosin-stained sections are shown; atherosclerotic plaques are delineated by dashed lines.

953 Scale bars, 100 μm. d) Body weight. e) Spleen weight. f) Total cholesterol level in serum,

954 evaluated by enzymatic methods.



957 Supplementary Figure X. Aortic arch samples were obtained from HF/HC-fed 20% WT-BMT

- 958 mice (n=11) or 20% KO-BMT mice (n=10) and gene expression was analyzed by qPCR 959 analysis.

9	8	7
1	υ	1

Sources:

988	1. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, Mills JL, Ricco JB,
989	Suresh KR and Murad MH. Global vascular guidelines on the management of chronic limb-
990	threatening ischemia. J Vasc Surg. 2019;69:38-125S.e40.
991	2. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC,
992	Mermel CH, Burtt N, Chavez A, et al. Age-Related Clonal Hematopoiesis Associated with
993	Adverse Outcomes. New England Journal of Medicine. 2014;371:2488-2498.
994	3. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta
995	N, Gabriel S, Ardissino D, et al. Clonal Hematopoiesis and Risk of Atherosclerotic
996	Cardiovascular Disease. New England Journal of Medicine. 2017;377:111-121.
997	4. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, McMichael JF, Schmidt
998	HK, Yellapantula V, Miller CA, et al. Age-related mutations associated with clonal
999	hematopoietic expansion and malignancies. Nature medicine. 2014;20:1472-8.
1000	5. Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, Chambert
1001	K, Mick E, Neale BM, Fromer M, et al. Clonal hematopoiesis and blood-cancer risk inferred
1002	from blood DNA sequence. N Engl J Med. 2014;371:2477-87.
1003	6. Bick AG, Pirruccello JP, Griffin GK, Gupta N, Gabriel S, Saleheen D, Libby P,
1004	Kathiresan S and Natarajan P. Genetic Interleukin 6 Signaling Deficiency Attenuates
1005	Cardiovascular Risk in Clonal Hematopoiesis. Circulation. 2020;141:124-131.
1006	7. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D,
1007	Delaneau O, O'Connell J, et al. The UK Biobank resource with deep phenotyping and genomic
1008	data. Nature. 2018;562:203-209.
1009	8. Smoller JW, Karlson EW, Green RC, Kathiresan S, MacArthur DG, Talkowski ME,
1010	Murphy SN and Weiss ST. An eMERGE Clinical Center at Partners Personalized Medicine.
1011	Journal of personalized medicine. 2016;6.
1012	9. Van Hout CV, Tachmazidou I, Backman JD, Hoffman JD, Liu D, Pandey AK, Gonzaga-
1013	Jauregui C, Khalid S, Ye B, Banerjee N, et al. Exome sequencing and characterization of 49,960
1014	individuals in the UK Biobank. Nature. 2020;586:749-756.
1015	10. Bick AG, Weinstock JS, Nandakumar SK, Fulco CP, Bao EL, Zekavat SM, Szeto MD,
1016	Liao X, Leventhal MJ, Nasser J, et al. Inherited causes of clonal haematopoiesis in 97,691 whole
1017	genomes. Nature. 2020;586:763-768.
1018	11. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC,
1019	Mermel CH, Burtt N, Chavez A, et al. Age-related clonal hematopoiesis associated with adverse
1020	outcomes. <i>N Engl J Med</i> . 2014;371:2488-98.
1021	12. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta
1022	N, Gabriel S, Ardissino D, et al. Clonal Hematopoiesis and Risk of Atherosclerotic
1023	Cardiovascular Disease. N Engl J Med. 2017;377:111-121.
1024	13. Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, Lee KM, Shao Q,
1025	Huffman JE, Natarajan P, et al. Genome-wide association study of peripheral artery disease in
1026	the Million Veteran Program. Nature medicine. 2019;25:1274-1279.
1027	14. Wu P, Gifford A, Meng X, Li X, Campbell H, Varley T, Zhao J, Carroll R, Bastarache L,
1028	Denny JC, et al. Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development
1029	and Initial Evaluation. JMIR Med Inform. 2019;7:e14325.

1030 15. Zekavat SM, Lin S-H, Bick AG, Liu A, Paruchuri K, Uddin MM, Ye Y, Yu Z, Liu X, 1031 Kamatani Y, et al. Hematopoietic mosaic chromosomal alterations and risk for infection among 1032 767,891 individuals without blood cancer. *medRxiv*. 2020:2020.11.12.20230821. 1033 16. Hernan MA, Brumback B and Robins JM. Marginal structural models to estimate the 1034 causal effect of zidovudine on the survival of HIV-positive men. *Epidemiology*. 2000;11:561-70. 1035 Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, Wu 17. 1036 CL, Sano S, Muralidharan S, Rius C, et al. Clonal hematopoiesis associated with TET2 1037 deficiency accelerates atherosclerosis development in mice. Science (New York, NY). 1038 2017;355:842-847. 1039 Fuster JJ, Zuriaga MA, Zorita V, MacLauchlan S, Polackal MN, Viana-Huete V, Ferrer-18. 1040 Pérez A, Matesanz N, Herrero-Cervera A, Sano S, et al. TET2-Loss-of-Function-Driven Clonal 1041 Hematopoiesis Exacerbates Experimental Insulin Resistance in Aging and Obesity. Cell reports. 1042 2020:33:108326. 1043 Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, Field JR, Pulley 19. 1044 JM, Ramirez AH, Bowton E, et al. Systematic comparison of phenome-wide association study of 1045 electronic medical record data and genome-wide association study data. Nat Biotechnol. 1046 2013;31:1102-10. 1047 Visconte V, M ON and H JR. Mutations in Splicing Factor Genes in Myeloid 20. 1048 Malignancies: Significance and Impact on Clinical Features. Cancers (Basel). 2019;11. 1049 21. Bondar T and Medzhitov R. p53-mediated hematopoietic stem and progenitor cell 1050 competition. Cell Stem Cell. 2010;6:309-22. 1051 Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, Di Giandomenico S, Lee JM, 22. 1052 Deblasio A, Menendez S, et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell. 1053 2009;4:37-48. 1054 TeKippe M, Harrison DE and Chen J. Expansion of hematopoietic stem cell phenotype 23. 1055 and activity in Trp53-null mice. Exp Hematol. 2003:31:521-7. 1056 Sano S, Oshima K, Wang Y, MacLauchlan S, Katanasaka Y, Sano M, Zuriaga MA, 24. 1057 Yoshiyama M, Goukassian D, Cooper MA, et al. Tet2-Mediated Clonal Hematopoiesis 1058 Accelerates Heart Failure Through a Mechanism Involving the IL-1beta/NLRP3 Inflammasome. 1059 J Am Coll Cardiol. 2018;71:875-886. 1060 Abplanalp WT, Cremer S, John D, Hoffmann J, Schuhmacher B, Merten M, Rieger MA, 25. 1061 Vasa-Nicotera M, Zeiher AM and Dimmeler S. Clonal Hematopoiesis-Driver DNMT3A 1062 Mutations Alter Immune Cells in Heart Failure. Circ Res. 2021;128:216-228. 1063 26. Sinha SK, Miikeda A, Fouladian Z, Mehrabian M, Edillor C, Shih D, Zhou Z, Paul MK, 1064 Charugundla S, Davis RC, et al. Local M-CSF (Macrophage Colony-Stimulating Factor) 1065 Expression Regulates Macrophage Proliferation and Apoptosis in Atherosclerosis. Arterioscler 1066 Thromb Vasc Biol. 2021;41:220-233. 1067 Klarin D, Verma SS, Judy R, Dikilitas O, Wolford BN, Paranipe I, Levin MG, Pan C, 27. 1068 Tcheandjieu C, Spin JM, et al. Genetic Architecture of Abdominal Aortic Aneurysm in the 1069 Million Veteran Program. Circulation. 2020. 1070 Shimizu K, Mitchell RN and Libby P. Inflammation and cellular immune responses in 28. 1071 abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26:987-94. 1072 29. Boesten LS, Zadelaar AS, van Nieuwkoop A, Hu L, Teunisse AF, Jochemsen AG, Evers 1073 B, van de Water B, Gijbels MJ, van Vlijmen BJ, et al. Macrophage p53 controls macrophage 1074 death in atherosclerotic lesions of apolipoprotein E deficient mice. Atherosclerosis. 2009;207:399-404. 1075

- 1076 30. Fuster JJ, Fernandez P, Gonzalez-Navarro H, Silvestre C, Nabah YN and Andres V.
- 1077 Control of cell proliferation in atherosclerosis: insights from animal models and human studies.
 1078 *Cardiovasc Res.* 2010;86:254-64.
- 1079 31. Guevara NV, Kim HS, Antonova EI and Chan L. The absence of p53 accelerates 1080 atherosclerosis by increasing cell proliferation in vivo. *Nat Med*, 1999;5:335-9.
- 1081 32. Mercer J, Figg N, Stoneman V, Braganza D and Bennett MR. Endogenous p53 protects
- vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout
 mice. *Circ Res.* 2005;96:667-74.
- Merched AJ, Williams E and Chan L. Macrophage-specific p53 expression plays a
 crucial role in atherosclerosis development and plaque remodeling. *Arterioscler Thromb Vasc Biol.* 2003;23:1608-14.
- 1087 34. Sanz-Gonzalez SM, Barquin L, Garcia-Cao I, Roque M, Gonzalez JM, Fuster JJ, Castells
- 1088 MT, Flores JM, Serrano M and Andres V. Increased p53 gene dosage reduces neointimal
- thickening induced by mechanical injury but has no effect on native atherosclerosis. *Cardiovasc Res.* 2007;75:803-12.
- 1091 35. van Vlijmen BJ, Gerritsen G, Franken AL, Boesten LS, Kockx MM, Gijbels MJ,
- 1092 Vierboom MP, van Eck M, van De Water B, van Berkel TJ, et al. Macrophage p53 deficiency
- leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ Res. 2001;88:780-6.
- 1094 36. Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, Gorbatov R,
- Sukhova GK, Gerhardt LM, Smyth D, et al. Local proliferation dominates lesional macrophageaccumulation in atherosclerosis. *Nat Med.* 2013;19:1166-72.
- 1097 37. Heyde A, Rohde D, McAlpine CS, Zhang S, Hoyer FF, Gerold JM, Cheek D, Iwamoto
 1098 Y, Schloss MJ, Vandoorne K, et al. Increased stem cell proliferation in atherosclerosis
- accelerates clonal hematopoiesis. *Cell*. 2021;184:1348-1361 e22.
- 1100 38. Fidler TP, Xue C, Yalcinkaya M, Hardaway B, Abramowicz S, Xiao T, Liu W, Thomas
- 1101 DG, Hajebrahimi MA, Pircher J, et al. The AIM2 inflammasome exacerbates atherosclerosis in
- 1102 clonal haematopoiesis. *Nature*. 2021;592:296-301.
- 1103